ALHAMBRA, Calif., May 7, 2024 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the first quarter ended March 31, 2024.
"We believe our strong first quarter performance continues to demonstrate the uniqueness of our platform, care model, and technology. Revenue growth of 20%, net income attributable to Astrana growth of 13% and adjusted EBITDA growth of 42% relative to the prior year quarter were primarily driven by solid membership growth across all lines of business and successful management of total cost of care for our members. Additionally, organic membership growth of 10% year-to-date increased our total number of lives managed to approximately one million. We also made further progress transitioning our members into full-risk arrangements, which we expect to account for approximately 60% of our total capitation revenue as of April 1, 2024. We believe our consistent execution against our strategic roadmap has set the stage for continued growth this year as we bring high-quality, high-value care to the communities we serve," said Brandon K. Sim, President and Chief Executive Officer of Astrana Health.
Financial Highlights for First Quarter Ended March 31, 2024:
All comparisons are to the quarter ended March 31, 2023 unless otherwise stated.
Recent Operating Highlights
Segment Results for the First Quarter Ended March 31, 2024:
Three Months Ended March 31, 2024 | ||||||||||||||
(in thousands) | Care | Care | Care | Other | Intersegment | Corporate | Consolidated | |||||||
Total revenues | $ 397,095 | $ 30,719 | $ 33,274 | $ — | $ (56,732) | $ — | $ 404,356 | |||||||
% change vs. prior year quarter | 26 % | 21 % | 9 % | 20 % | ||||||||||
Cost of services | 314,966 | 24,794 | 17,373 | — | (26,734) | — | 330,399 | |||||||
General and administrative(1) | 38,933 | 6,163 | 12,397 | — | (30,075) | 16,400 | 43,818 | |||||||
Total expenses | 353,899 | 30,957 | 29,770 | — | (56,809) | 16,400 | 374,217 | |||||||
Income (loss) from operations | $ 43,196 | $ (238) | $ 3,504 | $ — | $ 77 | (2) | $ (16,400) | $ 30,139 | ||||||
% change vs. prior year quarter | 94 % | (75) % | (39) % | 35 % | ||||||||||
(1) Balance includes general and administrative expenses and depreciation and amortization. |
(2) Income from operations for the intersegment elimination represents rental income from segments renting from other segments. Rental income is presented within other income which is not presented in the table. |
2024 Guidance:
Astrana is reiterating the following guidance for total revenue, net income attributable to Astrana, Adjusted EBITDA, and EPS - diluted, based on the Company's existing business, current view of existing market conditions and assumptions for the year ending December 31, 2024.
2024 Guidance Range | ||||
($ in millions) | Low | High | ||
Total revenue | $ 1,650.0 | $ 1,850.0 | ||
Net income attributable to Astrana Health, Inc. | $ 61.0 | $ 73.0 | ||
Adjusted EBITDA | $ 165.0 | $ 185.0 | ||
EPS – diluted | $ 1.28 | $ 1.52 | ||
See "Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA" and "Use of Non-GAAP Financial Measures" below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See "Forward-Looking Statements" below for additional information.
Conference Call and Webcast Information:
Astrana will host a conference call at 2:30 p.m. PT/5:30 p.m. ET today (Tuesday, May 7, 2024), during which management will discuss the results of the first quarter ended March 31, 2024. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled conference call time:
U.S. & Canada (Toll-Free): | +1 (888) 437-3179 |
International (Toll): | +1 (862) 298-0702 |
The conference call can also be accessed via webcast at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=y3Hig4E8.
An accompanying slide presentation will be available in PDF format on the "IR Calendar" page of the Company's website (https://ir.astranahealth.com/news-events/ir-calendar) after issuance of the earnings release and will be furnished as an exhibit to Astrana's current report on Form 8-K to be filed with the SEC, accessible at www.sec.gov.
Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.
Note About Consolidated Entities
The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities ("VIEs") in which the Company is the primary beneficiary. Noncontrolling interests represent third party equity ownership interests in the Company's consolidated entities (including certain VIEs). The amount of net income attributable to noncontrolling interests is disclosed in the Company's consolidated statements of income.
Note About Stockholders' Equity, Certain Treasury Stock and Earnings Per Share
As of the date of this press release, 41,048 holdback shares have not been issued to certain former shareholders of the Company's subsidiary, Astrana Health Management, Inc. ("AHM"), formerly known as Network Medical Management, Inc., who were AHM shareholders at the time of closing of the merger, as they have yet to submit properly completed letters of transmittal to Astrana in order to receive their pro rata portion of Astrana's common stock as contemplated under that certain Agreement and Plan of Merger, dated December 21, 2016, among Astrana, AHM, Apollo Acquisition Corp. ("Merger Subsidiary") and Kenneth Sim, M.D., as amended, pursuant to which Merger Subsidiary merged with and into AHM, with AHM as the surviving corporation. Pending such receipt, such former AHM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the merger. The Company's consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and Astrana is legally obligated to issue these shares in connection with the merger.
Shares of Astrana's common stock owned by Allied Physicians of California, a Professional Medical Corporation ("APC"), a VIE of the Company, are legally issued and outstanding but excluded from shares of common stock outstanding in the Company's consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. Such shares, therefore, are not included in the number of shares of common stock outstanding used to calculate the Company's earnings per share.
About Astrana Health, Inc.
Astrana is a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all. Leveraging its proprietary end-to-end technology solutions, Astrana operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.
Headquartered in Alhambra, California, Astrana serves over 10,000 providers and 1.0 million patients in value-based care arrangements. Its subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), accountable care organizations (ACOs), and care delivery entities across primary, multi-specialty, and ancillary care. For more information, please visit www.astranahealth.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company's guidance for the year ending December 31, 2024, ability to meet operational goals, ability to meet expectations in deployment of care coordination and management capabilities, ability to decrease cost of care while improving quality and outcomes, ability to deliver sustainable revenue and EBITDA growth as well as long-term value, ability to respond to the changing environment, and successful implementation of strategic growth plans, acquisition strategy, and merger integration efforts. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the SEC, including, without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and any subsequent quarterly reports on Form 10-Q.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
(626) 943-6491
This email address is being protected from spambots. You need JavaScript enabled to view it.
ASTRANA HEALTH, INC. | ||||
CONSOLIDATED BALANCE SHEETS | ||||
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) | ||||
March 31, | December 31, | |||
(Unaudited) | ||||
Assets | ||||
Current assets | ||||
Cash and cash equivalents | $ 334,796 | $ 293,807 | ||
Investment in marketable securities | 2,490 | 2,498 | ||
Receivables, net | 120,106 | 76,780 | ||
Receivables, net – related parties | 62,354 | 58,980 | ||
Income taxes receivable | — | 10,657 | ||
Other receivables | 1,783 | 1,335 | ||
Prepaid expenses and other current assets | 17,281 | 17,450 | ||
Total current assets | 538,810 | 461,507 | ||
Non-current assets | ||||
Land, property and equipment, net | 7,985 | 7,171 | ||
Intangible assets, net | 119,707 | 71,648 | ||
Goodwill | 410,267 | 278,831 | ||
Income taxes receivable | 15,943 | 15,943 | ||
Loans receivable, non-current | 47,412 | 26,473 | ||
Investments in other entities – equity method | 35,893 | 25,774 | ||
Investments in privately held entities | 6,396 | 6,396 | ||
Restricted cash | 645 | 345 | ||
Operating lease right-of-use assets | 39,152 | 37,396 | ||
Other assets | 4,067 | 1,877 | ||
Total non-current assets | 687,467 | 471,854 | ||
Total assets(1) | $ 1,226,277 | $ 933,361 | ||
Liabilities, mezzanine equity and equity | ||||
Current liabilities | ||||
Accounts payable and accrued expenses | $ 146,473 | $ 59,949 | ||
Fiduciary accounts payable | 7,792 | 7,737 | ||
Medical liabilities | 136,494 | 106,657 | ||
Income taxes payable | 5,522 | — | ||
Dividend payable | 638 | 638 | ||
Finance lease liabilities | 636 | 646 | ||
Operating lease liabilities | 5,007 | 4,607 | ||
Current portion of long-term debt | 20,750 | 19,500 | ||
Other liabilities | 31,960 | 18,940 | ||
Total current liabilities | 355,272 | 218,674 | ||
March 31, | December 31, | |||
Non-current liabilities | ||||
Deferred tax liability | 3,756 | 4,072 | ||
Finance lease liabilities, net of current portion | 1,015 | 1,033 | ||
Operating lease liabilities, net of current portion | 37,716 | 36,289 | ||
Long-term debt, net of current portion and deferred financing costs | 368,448 | 258,939 | ||
Other long-term liabilities | 7,652 | 3,586 | ||
Total non-current liabilities | 418,587 | 303,919 | ||
Total liabilities(1) | 773,859 | 522,593 | ||
Mezzanine equity | ||||
Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation ("APC") | (205,557) | (205,883) | ||
Stockholders' equity | ||||
Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and zero outstanding | — | — | ||
Series B Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series A Preferred stock); 555,555 issued and zero outstanding | — | — | ||
Common stock, par value $0.001; 100,000,000 shares authorized, 47,458,264 and 46,843,743 shares outstanding, excluding 10,584,340 and 10,584,340 Treasury shares, at March 31, 2024 and December 31, 2023, respectively | 48 | 47 | ||
Additional paid-in capital | 395,473 | 371,037 | ||
Retained earnings | 257,969 | 243,134 | ||
Total Stockholders' equity | 653,490 | 614,218 | ||
Non-controlling interest | 4,485 | 2,433 | ||
Total equity | 657,975 | 616,651 | ||
Total liabilities, mezzanine equity, and stockholders' equity | $ 1,226,277 | $ 933,361 | ||
(1)The Company's consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company's consolidated VIEs totaling $717.5 million and $540.8 million as of March 31, 2024 and December 31, 2023, respectively, and total liabilities of the Company's consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $179.6 million and $146.0 million as of March 31, 2024 and December 31, 2023, respectively. The VIE balances do not include $299.5 million of investment in affiliates and $110.1 million of amounts due to affiliates as of March 31, 2024 and $273.2 million of investment in affiliates and $107.3 million of amounts due to affiliates as of December 31, 2023 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. |
ASTRANA HEALTH, INC. CONSOLIDATED STATEMENTS OF INCOME (IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS) (UNAUDITED) | ||||
Three Months Ended March 31, | ||||
2024 | 2023 | |||
Revenue | ||||
Capitation, net | $ 365,910 | $ 300,204 | ||
Risk pool settlements and incentives | 17,377 | 13,462 | ||
Management fee income | 4,078 | 9,896 | ||
Fee-for-service, net | 15,937 | 12,062 | ||
Other revenue | 1,054 | 1,620 | ||
Total revenue | 404,356 | 337,244 | ||
Operating expenses | ||||
Cost of services, excluding depreciation and amortization | 330,399 | 289,397 | ||
General and administrative expenses | 38,722 | 21,182 | ||
Depreciation and amortization | 5,096 | 4,292 | ||
Total expenses | 374,217 | 314,871 | ||
Income from operations | 30,139 | 22,373 | ||
Other income (expense) | ||||
Income from equity method investments | 632 | 2,484 | ||
Interest expense | (7,585) | (3,269) | ||
Interest income | 3,996 | 3,009 | ||
Unrealized gain (loss) on investments | 1,099 | (6,392) | ||
Other (loss) income | (4,277) | 1,204 | ||
Total other expense, net | (6,135) | (2,964) | ||
Income before provision for income taxes | 24,004 | 19,409 | ||
Provision for income taxes | 7,142 | 6,921 | ||
Net income | 16,862 | 12,488 | ||
Net income (loss) attributable to non-controlling interest | 2,027 | (644) | ||
Net income attributable to Astrana Health, Inc. | $ 14,835 | $ 13,132 | ||
Earnings per share – basic | $ 0.31 | $ 0.28 | ||
Earnings per share – diluted | $ 0.31 | $ 0.28 | ||
EBITDA
Set forth below are reconciliations of Net Income to EBITDA and Adjusted EBITDA as well as the reconciliation to Adjusted EBITDA margin for the three months ended March 31, 2024 and 2023. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.
Three Months Ended March 31, | |||||
(in thousands) | 2024 | 2023 | |||
Net income | $ 16,862 | $ 12,488 | |||
Interest expense | 7,585 | 3,269 | |||
Interest income | (3,996) | (3,009) | |||
Provision for income taxes | 7,142 | 6,921 | |||
Depreciation and amortization | 5,096 | 4,292 | |||
EBITDA | 32,689 | 23,961 | |||
Income from equity method investments | (632) | (249) | |||
Other, net | 4,440 | (1) | 1,402 | (2) | |
Stock-based compensation | 5,748 | 3,445 | |||
APC excluded asset costs | — | 1,266 | |||
Adjusted EBITDA | $ 42,245 | $ 29,825 | |||
Total revenue | $ 404,356 | $ 337,244 | |||
Adjusted EBITDA margin | 10 % | 9 % | |||
(1) Other, net for the three months ended March 31, 2024 relates to a financial guarantee via a letter of credit that we provided almost three years ago in support of two local provider-led ACOs, non-cash changes related to change in the fair value of our financing obligation to purchase the remaining equity interests in one of our investments, non-cash changes related to change in the fair value of the Company's Collar Agreement, and transaction costs incurred for our investments and tax restructuring fees. |
(2) Other, net for the three months ended March 31, 2023 relates to changes in the fair value of our financing obligation to purchase the remaining equity interest in one of our investments. |
Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA | ||||
2024 Guidance Range | ||||
(in thousands) | Low | High | ||
Net income | $ 71,500 | $ 85,500 | ||
Interest expense | 14,500 | 12,500 | ||
Provision for income taxes | 36,500 | 44,500 | ||
Depreciation and amortization | 14,500 | 14,500 | ||
EBITDA | 137,000 | 157,000 | ||
Income from equity method investments | (5,000) | (5,000) | ||
Other, net | 6,000 | 6,000 | ||
Stock-based compensation | 27,000 | 27,000 | ||
Adjusted EBITDA | $ 165,000 | $ 185,000 | ||
Use of Non-GAAP Financial Measures
This press release contains the non-GAAP financial measures EBITDA, Adjusted EBITDA and Adjusted EBITDA margin, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles ("GAAP") is net income. These measures are not in accordance with, or alternatives to GAAP, and may be calculated differently from similar non-GAAP financial measures used by other companies. The Company uses Adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring and non-cash transactions, stock-based compensation, and APC excluded assets costs. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.
The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company's ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. Other companies may calculate both EBITDA and Adjusted EBITDA differently, limiting the usefulness of these measures for comparative purposes. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.
| Last Trade: | US$33.48 |
| Daily Change: | 0.01 0.03 |
| Daily Volume: | 138,684 |
| Market Cap: | US$1.530B |
November 08, 2024 November 07, 2024 July 15, 2024 February 27, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
